SG11201810914VA - Compositions and methods for diagnosing lung cancers using gene expression profiles - Google Patents
Compositions and methods for diagnosing lung cancers using gene expression profilesInfo
- Publication number
- SG11201810914VA SG11201810914VA SG11201810914VA SG11201810914VA SG11201810914VA SG 11201810914V A SG11201810914V A SG 11201810914VA SG 11201810914V A SG11201810914V A SG 11201810914VA SG 11201810914V A SG11201810914V A SG 11201810914VA SG 11201810914V A SG11201810914V A SG 11201810914VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gene expression
- compositions
- methods
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352865P | 2016-06-21 | 2016-06-21 | |
| PCT/US2017/038571 WO2017223216A1 (en) | 2016-06-21 | 2017-06-21 | Compositions and methods for diagnosing lung cancers using gene expression profiles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810914VA true SG11201810914VA (en) | 2019-01-30 |
Family
ID=60783927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810914VA SG11201810914VA (en) | 2016-06-21 | 2017-06-21 | Compositions and methods for diagnosing lung cancers using gene expression profiles |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11661632B2 (ru) |
| EP (1) | EP3472361A4 (ru) |
| JP (1) | JP2019522478A (ru) |
| KR (1) | KR20190026769A (ru) |
| CN (1) | CN109715830A (ru) |
| AU (1) | AU2017281099A1 (ru) |
| BR (1) | BR112018076528A2 (ru) |
| CA (1) | CA3026809A1 (ru) |
| IL (1) | IL263635A (ru) |
| MX (1) | MX2018016051A (ru) |
| RU (1) | RU2018145532A (ru) |
| SG (1) | SG11201810914VA (ru) |
| WO (1) | WO2017223216A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3368686A1 (en) | 2015-10-30 | 2018-09-05 | Exact Sciences Development Company, LLC | Multiplex amplification detection assay and isolation and detection of dna from plasma |
| CN116064796A (zh) | 2016-05-05 | 2023-05-05 | 精密科学公司 | 通过分析甲基化dna来检测肺肿瘤 |
| CN108624692B (zh) * | 2018-06-25 | 2021-08-03 | 上海伯豪医学检验所有限公司 | 用于肺部微小结节良恶性甄别的基因标志物及其用途 |
| AU2018211956A1 (en) | 2017-01-27 | 2019-07-25 | Exact Sciences Corporation | Detection of colon neoplasia by analysis of methylated DNA |
| WO2019126343A1 (en) * | 2017-12-19 | 2019-06-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods for diagnosing lung cancers using gene expression profiles |
| BR112021009795A2 (pt) * | 2018-11-27 | 2021-08-17 | Exact Sciences Development Company, Llc | métodos de caracterização e para caracterizar uma amostra, kit e composição |
| KR102199000B1 (ko) * | 2020-09-25 | 2021-01-06 | 이화여자대학교 산학협력단 | 간암 진단을 위한 신규 바이오마커 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| WO2003078662A1 (en) | 2002-03-13 | 2003-09-25 | Genomic Health | Gene expression profiling in biopsied tumor tissues |
| JP5150909B2 (ja) * | 2005-07-27 | 2013-02-27 | オンコセラピー・サイエンス株式会社 | 食道癌を診断する方法 |
| JP2009502115A (ja) * | 2005-07-27 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | 小細胞肺癌の診断方法 |
| WO2007141004A1 (en) * | 2006-06-09 | 2007-12-13 | Bayer Healthcare Ag | Use of adipsin (adn) as a therapeutic or diagnostic target |
| US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
| US8476420B2 (en) * | 2007-12-05 | 2013-07-02 | The Wistar Institute Of Anatomy And Biology | Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells |
| ES2559758T3 (es) * | 2008-09-09 | 2016-02-15 | Somalogic, Inc. | Biomarcadores de cáncer de pulmón y usos de los mismos |
| GB201000688D0 (en) * | 2010-01-15 | 2010-03-03 | Diagenic Asa | Product and method |
| CA2801110C (en) * | 2010-07-09 | 2021-10-05 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| EP2527459A1 (en) * | 2011-05-02 | 2012-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Blood-based gene detection of non-small cell lung cancer |
| EP3998347A1 (en) * | 2012-04-10 | 2022-05-18 | Vib Vzw | Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway |
| EP2841603A4 (en) * | 2012-04-26 | 2016-05-25 | Allegro Diagnostics Corp | METHODS OF ASSESSING THE STATUS OF LUNG CANCER |
| US20150315643A1 (en) | 2012-12-13 | 2015-11-05 | Baylor Research Institute | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis |
| EP3169814B1 (en) | 2014-07-14 | 2022-05-04 | Veracyte, Inc. | Methods for evaluating lung cancer status |
| WO2019126343A1 (en) | 2017-12-19 | 2019-06-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods for diagnosing lung cancers using gene expression profiles |
-
2017
- 2017-06-21 KR KR1020197001660A patent/KR20190026769A/ko not_active Application Discontinuation
- 2017-06-21 CA CA3026809A patent/CA3026809A1/en not_active Abandoned
- 2017-06-21 US US16/312,036 patent/US11661632B2/en active Active
- 2017-06-21 RU RU2018145532A patent/RU2018145532A/ru not_active Application Discontinuation
- 2017-06-21 AU AU2017281099A patent/AU2017281099A1/en not_active Abandoned
- 2017-06-21 CN CN201780045321.5A patent/CN109715830A/zh active Pending
- 2017-06-21 MX MX2018016051A patent/MX2018016051A/es unknown
- 2017-06-21 BR BR112018076528-7A patent/BR112018076528A2/pt not_active Application Discontinuation
- 2017-06-21 SG SG11201810914VA patent/SG11201810914VA/en unknown
- 2017-06-21 WO PCT/US2017/038571 patent/WO2017223216A1/en unknown
- 2017-06-21 EP EP17816148.5A patent/EP3472361A4/en not_active Withdrawn
- 2017-06-21 JP JP2018567154A patent/JP2019522478A/ja active Pending
-
2018
- 2018-12-10 IL IL263635A patent/IL263635A/en unknown
-
2023
- 2023-04-25 US US18/306,548 patent/US20230366034A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018076528A2 (pt) | 2019-04-02 |
| KR20190026769A (ko) | 2019-03-13 |
| RU2018145532A (ru) | 2020-07-23 |
| WO2017223216A1 (en) | 2017-12-28 |
| US20230366034A1 (en) | 2023-11-16 |
| JP2019522478A (ja) | 2019-08-15 |
| US11661632B2 (en) | 2023-05-30 |
| RU2018145532A3 (ru) | 2020-10-16 |
| AU2017281099A1 (en) | 2019-01-03 |
| US20200123613A1 (en) | 2020-04-23 |
| IL263635A (en) | 2019-02-03 |
| EP3472361A1 (en) | 2019-04-24 |
| CN109715830A (zh) | 2019-05-03 |
| CA3026809A1 (en) | 2017-12-28 |
| MX2018016051A (es) | 2019-08-29 |
| EP3472361A4 (en) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810914VA (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201902925PA (en) | Phenotype/disease specific gene ranking using curated, gene library and network based data structures | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201804957VA (en) | Neoantigen identification, manufacture, and use | |
| SG11201806282XA (en) | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies | |
| SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
| SG11201809643UA (en) | Compositions and methods of treating huntington's disease | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201810611YA (en) | Coumarin compounds and their uses as fluorescent labels | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201408385TA (en) | Methods of detecting diseases or conditions | |
| SG11201804707YA (en) | Photonic crystal fiber assembly | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care |